

Receipt date: 12/21/2009

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/578,589-Conf. #9455
				Filing Date	December 13, 2006
				First Named Inventor	Anne-Sophie Bessis
				Art Unit	1625
				Examiner Name	T. A. Solola
Sheet	1	of	2	Attorney Docket Number	65517(53196)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-2003/0149049	08-07-2003	Arkin et al.	
	AB	US-3,991,064	11-09-1976	Brown et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
	BA	WO-03/027080	04-03-2003	Mitsubishi Pharma Corporation, Sanofi-Synthelabo		
	BB	WO-2004/085408	10-07-2004	Mitsubishi Pharma Corporation, Sanofi-Synthelabo		
	BC	WO-2004/052864	06-24-2004	Pfizer Products Inc.		
	BD	WO-01/02375	01-11-2001	AXYS Pharmaceuticals, Inc.		
	BE	WO-01/54507	08-02-2001	Akkadix Corporation		
	BF	WO-03/037888	05-08-2003	Mitsubishi Pharma Corporation, Sanofi-Synthelabo		
	BG	WO-91/04250	04-04-1991	Schering Aktiengesellschaft Berlin Und Bergkamen		
	BH	GB-950,872	02-26-1964	Boissier, et al.		
	BI	WO-03/066595	08-14-2003	Euro-celtique S.A.		
	BJ	WO-2004/011441	02-05-2004	Euro-celtique S.A.		
	BK	WO-2004/014902	02-19-2004	Astrazeneca AB		
	BL	WO-2004/029031	04-08-2004	Euro-celtique, S.A.		
	BM	WO-2004/038374	05-06-2004	Merck & Co., Inc.		
	BN	WO-2004/058754	07-15-2004	Euro-celtique S.A.		

Examiner Signature	/Taofiq Solola/	Date Considered	03/25/2010
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.S./

Receipt date: 12/21/2009

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/578,589-Conf. #9455
				Filing Date	December 13, 2006
				First Named Inventor	Anne-Sophie Bessis
				Art Unit	1625
				Examiner Name	T. A. Solola
Sheet	2	of	2	Attorney Docket Number	65517(53196)

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Rogers, et al., Neurobiology of Aging, Vol. 17, No. 5, pp. 681-686 (1996).	
	CB	Yan, et al., J. Comb. Chem., Vol. 5, No. 5, pp. 547-559 (2003).	
	CC	Phillips, et al., J. Med. Chem., Vol. 35, No. 4, pp. 743-750 (1992).	
	CD	Toja, E. et al., Farmaco Sci., Vol. 39, No. 5, pp. 450-462 (1984).	
	CE	CAS Registry No. 695195-63-2, Chemical Library, Supplier: Chemical Block Ltd, CAS Registry (2004)	
	CF	<del>Copy of Opposition filed in the name of Sanofi-Aventis in corresponding European Patent No. 1 685 105 B1.</del>	
	CG	<del>Copy of Opposition filed in the name of Dr. Thorsten Bausch in corresponding European Patent No. 1 685 105 B1.</del>	

Examiner Signature	/Taofiq Solola/	Date Considered	03/25/2010
-----------------------	-----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

BOS2 771136.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.S./